Basiliximab decreases the incidence of acute rejection after intestinal transplantation

被引：40

作者：

Sudan, DL ^{[1
]}

Chinnakotla, S ^{[1
]}

Horslen, S ^{[1
]}

Iyer, K ^{[1
]}

Fox, I ^{[1
]}

Shaw, B ^{[1
]}

Langnas, AN ^{[1
]}

机构：

[1] Univ Nebraska, Med Ctr, Omaha, NE 68198 USA

来源：

TRANSPLANTATION PROCEEDINGS | 2002年 / 34卷 / 03期

关键词：

D O I：

10.1016/S0041-1345(02)02681-7

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：940 / 941

页数：2

共 5 条

[1] Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody [J].

Kahan, BD ;

Rajagopalan, PR ;

Hall, M .

TRANSPLANTATION, 1999, 67 (02) :276-284

[2] Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients [J].

Nashan, B ;

Moore, R ;

Amlot, P ;

Schmidt, AG ;

Abeywickrama, K ;

Soulillou, JP .

LANCET, 1997, 350 (9086) :1193-1198

[3] Induction therapy for clinical intestinal transplantation: Comparison of four different regimens [J].

Pinna, AD ;

Weppler, D ;

Nery, JR ;

Khan, F ;

Ruiz, P ;

Kato, T ;

De Faria, W ;

Berho, M ;

Tzakis, AG .

TRANSPLANTATION PROCEEDINGS, 2000, 32 (06) :1193-1194

[4] Incidence, timing, and histologic grade of acute rejection in small bowel transplant recipients [J].

Sudan, DL ;

Kaufman, S ;

Horslen, S ;

Fox, I ;

Shaw, BW ;

Langnas, A .

TRANSPLANTATION PROCEEDINGS, 2000, 32 (06) :1199-1199

[5]

Sudan DL, 2000, AM J GASTROENTEROL, V95, P1506

← 1 →